tirzepatide is fda approved approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA confirms tirzepatide shortage is

Scientists study it as a model for how activating two receptors together behaves differently from activating just one, comparing it against single-receptor GLP-1 compounds and newer triple-receptor designs like retatrutide

By doing that, you signal your body to preserve muscle

For a smaller number of people, it may lead to weight loss due to appetite loss or increased energy burn from restlessness

Starting at 2mg reduces nausea rates significantly compared to starting at 4mg, but it also delays the onset of meaningful appetite suppression by approximately 4 weeks

Avoid the inner arm and anything close to the shoulder joint